# US 2006/0068456 A1 · Methods for screening and identifying compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0068456 A1
- Document ID: US20060068456A1
- Status: Published application
- Kind: A1
- Application number: 11/266,030
- Filed: 2005-11-02
- Published: 2006-03-30
- Earliest claimed: 2003-08-04
- Assignees: Bayer Pharmaceuticals Corporation
- Inventors: James Landro; David Osterman; Walter Pickett
- Web page: https://patentgrep.com/patent/US20060068456A1

## CPC

- C12Q 1/25: involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/48: involving transferase
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for assessing enzyme activity utilizing a phase partition system. In addition, the present invention also relates to methods for screening and identifying compounds that may be used, for example, for the treatment of diabetes, diabetes-related disorders, obesity, cardiovascular disease, cancer, and other diseases or disorders, using this phase partition system.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

A method of treating diabetes, diabetes-related disorders, obesity, cardiovascular disease, and cancer comprising administering to a mammal a therapeutically effective amount of a compound identified by the method comprising
combining an enzyme, radiolabeled substrate(s) and test compounds, adding a phase-partition scintillation fluid: incubating the reaction for at least two hours: and detecting enzyme activity,
wherein said reaction does not require mixing following addition of the phase-partition scintillation fluid and wherein said reaction is conducted in a single reaction vessel.

### Claim 32 (depends on 31)

The method of claim 31, wherein said compound is administered in combination with one or more pharmaceutical agents.

### Claim 33

A pharmaceutical composition comprising a compound identified by the method comprising
combining an enzyme, radiolabeled substrate(s) and test compounds: adding a phase-partition scintillation fluid: incubating the reaction for at least two hours: and detecting enzyme activity,
wherein said reaction does not require mixing following addition of the phase-partition scintillation fluid and wherein said reaction is conducted in a single reaction vessel, in combination with a pharmaceutically acceptable carrier.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, further comprising one or more pharmaceutical agents.
